SUNNYVALE, Calif.--Hyseq, a genomics company here, has signed its first pharmacogenomics agreement to work with the University of California, San Francisco, to study genes that may play important roles in the development of arteriosclerotic heart disease, stroke, diabetes, hypertension, and related metabolic disorders. In terms of the amount of sequence data generated, Hyseq claims the collaboration will be the largest ever in the cardiovascular field.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.